Related references
Note: Only part of the references are listed.Improved Outcomes after Allogenic Hematopoietic Stem Cell Transplantation with Fludarabine/Treosulfan for Patients with Myelodysplastic Syndromes
Eileen Wedge et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial
Dietrich Wilhelm Beelen et al.
LANCET HAEMATOLOGY (2020)
Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis
Vipul Sheth et al.
BONE MARROW TRANSPLANTATION (2019)
Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin's lymphoma
Young-Woo Jeon et al.
ANNALS OF HEMATOLOGY (2019)
Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Francesco Saraceni et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation
Avichai Shimoni et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML
Udo Holtick et al.
ANNALS OF HEMATOLOGY (2017)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
Bart L. Scott et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Long-Term Outcome After a Treosulfan-Based Conditioning Regimen for Patients With Acute Myeloid Leukemia: a Report From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Arnon Nagler et al.
CANCER (2017)
Survival Advantage and Comparable Toxicity in Reduced Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplantation
Ioanna Sakellari et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
FLAMSA reduced-intensity conditioning is equally effective in AML patients with primary induction failure as well as in first or second complete remission
Udo Holtick et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia
Jens Marcus Chemnitz et al.
ANNALS OF HEMATOLOGY (2012)
Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation
Christoph Schmid et al.
BLOOD (2012)
Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need
Avichai Shimoni et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2011)
Conditioning with Treosulfan and Fludarabine followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Eneida R. Nemecek et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Retrospective analysis of treosulfan-based conditioning in comparison with standard conditioning in patients with myelodysplastic syndrome
I. Hilgendorf et al.
BONE MARROW TRANSPLANTATION (2011)
Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Hematologic Malignancies After Dose-Escalated Treosulfan/Fludarabine Conditioning
Jochen Casper et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Defining the Intensity of Conditioning Regimens: Working Definitions
Andrea Bacigalupo et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission
C. Schmid et al.
BONE MARROW TRANSPLANTATION (2008)
Hyperacute GVM: risk factors, outcomes, and clinical implications
Rima M. Saliba et al.
BLOOD (2007)
Fludarabine and treosulfan: A novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes
Avichai Shimoni et al.
LEUKEMIA & LYMPHOMA (2007)
Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation
Christoph Schmid et al.
BLOOD (2006)
Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS)
N Kröger et al.
BONE MARROW TRANSPLANTATION (2006)
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report
AH Filipovich et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2005)
Treosulfan and fludarabine:: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation
J Casper et al.
BLOOD (2004)
Share Paper
